Table S4.

Logistic regression analysis of the factors associated with SUA decline

	Univariate logistic regression analysis
	OR	95% CI	P-value
Sex
Male	Reference
Female	0.620	0.283–1.356	0.231
Age	0.998	0.964–1.033	0.916
Dose
50 mg	Reference
100 mg	0.783	0.257–2.391	0.668
150 mg	0.667	0.073–6.111	0.720
ARBs pretreatment
IRB	Reference
ARBs–IRB switch	2.507	1.088–5.774	0.031*
Diabetic nephropathy
Stage II	1.009	0.429–2.373	0.984
Stage III	0.560	0.174–1.801	0.331
Myocardial disease	0.600	0.128–2.823	0.518
Cerebrovascular disease	0.600	0.128–2.823	0.518
Arteriosclerosis	ND	0.000–ND	0.999
Diabetic disease duration	0.948	0.898–1.000	0.052
History of alcohol intake	2.364	1.044–5.352	0.039*
SBP baseline	0.980	0.927–1.036	0.481
DBP baseline	0.965	0.905–1.029	0.274
HbA1c baseline	0.965	0.676–1.379	0.847
SCr baseline	1.908	0.482–7.553	0.357
SUA baseline	1.714	1.168–2.515	0.006**
	Multiple logistic regression analysis
	OR	95% CI	P-value
ARBs–IRB switch	2.710	1.028–7.144	0.044*
SUA baseline	1.609	1.050–2.467	0.029*
History of alcohol intake	1.576	0.612–4.057	0.346

Notes: SUA decline after 6–12 months was introduced as dependent variable and was coded 1.

^*P<0.05;

^**P<0.01.

Abbreviations: ARB, angiotensin II receptor blockers; CI, confidence interval; DBP, diastolic blood pressure; HbA_1c, glycated hemoglobin; IRB, irbesartan; OR, odds ratio; ND, not determined; SBP, systolic blood pressure; SCr, serum creatinine; SUA, serum uric acid.